1. Home
  2. BKT vs AGEN Comparison

BKT vs AGEN Comparison

Compare BKT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Income Trust Inc. (The)

BKT

BlackRock Income Trust Inc. (The)

HOLD

Current Price

$9.73

Market Cap

337.5M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.85

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKT
AGEN
Founded
N/A
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.5M
274.8M
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
BKT
AGEN
Price
$9.73
$7.85
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
136.3K
873.0K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.96
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.52
Revenue Growth
N/A
89.95
52 Week Low
$9.73
$2.71
52 Week High
$11.49
$8.85

Technical Indicators

Market Signals
Indicator
BKT
AGEN
Relative Strength Index (RSI) 28.03 54.50
Support Level N/A $2.97
Resistance Level $10.65 $8.64
Average True Range (ATR) 0.12 0.43
MACD -0.04 -0.10
Stochastic Oscillator 17.84 54.07

Price Performance

Historical Comparison
BKT
AGEN

About BKT BlackRock Income Trust Inc. (The)

Blackrock Income Trust Inc is a closed-end management investment company. Its investment objective is to manage a portfolio of high-quality securities to achieve both preservation of capital and high monthly income. The fund seeks to achieve its investment objective by investing at least 65% of its assets in mortgage-backed securities.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: